

480 The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed embodiments. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

#### WHAT IS CLAIMED IS

1. A crystalline polymorph of Cefdinir with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of  $8.1 \pm 0.1^\circ$ ,  $10.7 \pm 0.1^\circ$ ,  $12.1 \pm 0.1^\circ$ ,  $13.7 \pm 0.1^\circ$ ,  
5  $17.8 \pm 0.1^\circ$ ,  $19.0 \pm 0.1^\circ$ ,  $20.4 \pm 0.1^\circ$ ,  $21.5 \pm 0.1^\circ$ ,  $22.2 \pm 0.1^\circ$ ,  $23.0 \pm 0.1^\circ$ ,  $24.3 \pm 0.1^\circ$ , and  $25.5 \pm 0.1^\circ$ .
2. A crystalline polymorph of Cefdinir prepared by a process comprising:  
(a) suspending Form I of Cefdinir in a solvent;  
(b) isolating the desired polymorph from the suspension of step (a).
3. The crystalline polymorph of claim 2 wherein the solvent is water.
4. The crystalline polymorph of claim 2 wherein the solvent is ethanol.
5. The crystalline polymorph of claim 2 wherein the solvent is acetonitrile.
6. The crystalline polymorph of claim 2 wherein the solvent is formamide.
7. The crystalline polymorph of claim 2 wherein the solvent is N-methylpyrrolidinone.
8. The crystalline polymorph of claim 2 wherein the solvent is triethylamine.
9. The crystalline polymorph of claim 2 wherein the solvent is toluene.
10. The crystalline polymorph of claim 2 wherein the solvent is ethyl acetate.
11. The crystalline polymorph of claim 2 wherein the solvent is tetrahydrofuran.
12. The crystalline polymorph of claim 2 wherein the solvent is dioxane.
13. The crystalline polymorph of claim 2 wherein the solvent is dichloromethane.

14. The crystalline polymorph of claim 2 wherein the solvent is hexane.
15. The crystalline polymorph of claim 2 wherein the solvent is acetone.
16. The crystalline polymorph of claim 2 wherein the solvent is methyl ethyl ketone.
17. The crystalline polymorph of claim 2 wherein the solvent is dimethylsulfoxide.
18. The crystalline polymorph of claim 2 wherein the solvent is pyridine.
19. The crystalline polymorph of claim 2 wherein the solvent is nitromethane.
20. The crystalline polymorph of claim 2 wherein the solvent is a 1:1 mixture of water and ethanol.
21. The crystalline polymorph of claim 2 wherein the solvent is a 1:1 mixture of water and acetonitrile.
22. The crystalline polymorph of claim 2 wherein the solvent is a 1:1 mixture of water and acetone.
23. The crystalline polymorph of claim 1 wherein the suspension of step (a) has about 300 mg of Form I of Cefdinir.
24. The crystalline polymorph of claim 2 wherein step (a) is conducted at about 20 °C to about 40 °C.
25. The crystalline polymorph of claim 2 wherein step (a) is conducted at about 23 °C.
26. The crystalline polymorph of claim 2 wherein step (a) is conducted for about 1 to about 8 weeks.
27. A process for preparing a crystalline polymorph of Cefdinir, the process comprising:
  - (a) suspending Form I of Cefdinir in a solvent;
  - (b) isolating the desired polymorph from the suspension of step (a).

28. The crystalline polymorph of claim 27 wherein the solvent is water.
29. The crystalline polymorph of claim 27 wherein the solvent is ethanol.
30. The crystalline polymorph of claim 27 wherein the solvent is acetonitrile.
31. The crystalline polymorph of claim 27 wherein the solvent is formamide.
32. The crystalline polymorph of claim 27 wherein the solvent is N-methylpyrrolidinone.
33. The crystalline polymorph of claim 27 wherein the solvent is triethylamine.
34. The crystalline polymorph of claim 27 wherein the solvent is toluene.
35. The crystalline polymorph of claim 27 wherein the solvent is ethyl acetate.
36. The crystalline polymorph of claim 27 wherein the solvent is tetrahydrofuran.
37. The crystalline polymorph of claim 27 wherein the solvent is dioxane.
38. The crystalline polymorph of claim 27 wherein the solvent is dichloromethane.
39. The crystalline polymorph of claim 27 wherein the solvent is hexane.
40. The crystalline polymorph of claim 27 wherein the solvent is acetone.
41. The crystalline polymorph of claim 27 wherein the solvent is methyl ethyl ketone.
42. The crystalline polymorph of claim 27 wherein the solvent is dimethylsulfoxide.
43. The crystalline polymorph of claim 27 wherein the solvent is pyridine.
44. The crystalline polymorph of claim 27 wherein the solvent is nitromethane.
45. The crystalline polymorph of claim 27 wherein the solvent is a 1:1 mixture of water and ethanol.

46. The crystalline polymorph of claim 27 wherein the solvent is a 1:1 mixture of water and acetonitrile.
47. The crystalline polymorph of claim 27 wherein the solvent is a 1:1 mixture of water and acetone.
48. The process of claim 27 wherein the suspension of step (a) has about 300 mg of Form I of Cefdinir.
49. The process of claim 27 wherein step (a) is conducted at about 20 °C to about 40 °C.
50. The process of claim 27 wherein step (a) is conducted at about 23 °C.
51. The process of claim 27 wherein step (a) is conducted for about 1 to about 8 weeks.
52. A pharmaceutical composition comprising the crystalline polymorph of claim 1 in combination with a pharmaceutically acceptable carrier.